- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02534324
The Effect of Pre-discharge Blood Pressure of Patients With Asymptomatic Severe Hypertension in Emergency Department
March 13, 2016 updated by: Khrongwong Musikatavorn, MD., Chulalongkorn University
The Effect of Pre-discharge Blood Pressure on the Follow-up Outcomes After Managing the Patients With Asymptomatic Severe Hypertension in Emergency Department
The current guideline of asymptomatic severe hypertension (ASH) treatment in emergency department (ED) recommends through low level of evidence that the patients should not be rapidly decreased their BP in ED but instead receive oral antihypertensive treatment and close outpatient follow-up is needed.
Unfortunately, there was some ambiguity in the time point of BP measurement in ED described in the past literature because high BP on ED admission may significantly decrease within hours without any medications.
The importance of pre-ED discharge BP, which can still be critically high, that may affect the follow-up outcome has never been investigated.
The study aim of this study is to evaluate the physicians' treatment strategies as well as immediate clinical outcomes between patients with severely- and moderately-elevated pre-discharge BP after management of ASH its in ED during the recent recommendation.
The secondary outcome is to compare the BP at follow-up in these two groups.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The investigators will follow the patients with asymptomatic severe hypertension who attend ED of King Chulalongkorn Memorial Hospital (KCMH), an urban, 1,500-bed, university-affiliated, tertiary care hospital as well as treatment strategies.
A management strategy whether to start the drugs in ED with or without a period of observation or immediately after discharge without any observation depends on the treating physicians' judgment.
The investigators predefined the pre-discharge BP at ED into two groups; high BP (pre-discharge SBP < 180 mmHg) and severely high BP (pre-discharge SBP >= 180mmHg) groups.
Every eligible patient was scheduled for the internal medicine clinic for continuous care of the high blood pressure within 3-7 days after discharge.
Medical records were retrieved for the follow-up BP, compliance and associated adverse events at the clinic.
The investigators will make telephone follow-ups to the participants or their contact personnel in every case at 10 days after ED presentation to identify the deceased cases or those with major morbidity as well as the compliance to their medications.
Study Type
Observational
Enrollment (Actual)
146
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Bangkok
-
Patumwan, Bangkok, Thailand, 10330
- King Chulalongkorn Memorial Hospital, Faculty of Medicine, Chulalongkorn University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Adult patients (≥18 years old) who presented in our ED with systolic BP (SBP) greater or equal to 180 mmHg and diastolic BP (DBP) ≥ 100 mmHg were consecutively enrolled in this study.
Description
Inclusion Criteria:
- Adult patients ≥18 years old
- Systolic BP (SBP) greater or equal to 180 mmHg
- Diastolic BP (DBP) ≥ 100 mmHg
Exclusion Criteria:
- Acute end-organ damage related to severe hypertension that required rapid intravenous antihypertensive drugs for acute treatment involving cardiovascular (acute chest pain, heart failure, acute coronary syndromes, acute aortic syndromes), renal (acute kidney injury), ocular (retinal hemorrhage or hypertensive retinopathy) and central nervous system (seizure, acute cerebrovascular diseases, hypertensive encephalopathy)
- Hypertension caused by medical toxicology (e.g. use of sympathomimetic drugs (amphetamine and its derivatives), alcohol withdrawal syndrome
- Significantly decreased renal function (serum creatinine ≥ 1.5 mg/dL or creatinine clearance ≤ 30 ml/min)
- Pregnant women
- Moderate to severe pain (pain score on visual analog scale ≥ 5 centimeters out of 10)
- BP decrease to less than 180 mmHg after 10-minute bed rest without any medical treatment
- Having concurrent medical conditions that needed hospitalization.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
High SBP+antihypertensive meds
Patients with pre-discharge systolic blood pressure at discharge < 180 mmHg
|
Antihypertensive medications will be given to newly-diagnosed or non-compliant cases.
The additional oral antihypertensive drugs instruction to adjust their current regimens will be given to the patients with underlying hypertension for more BP control.
The choices of drugs will be at discretion of treating physicians.
Other Names:
|
|
Severely high SBP+antihypertensive meds
Patients with pre-discharge systolic blood pressure at discharge >= 180 mmHg
|
Antihypertensive medications will be given to newly-diagnosed or non-compliant cases.
The additional oral antihypertensive drugs instruction to adjust their current regimens will be given to the patients with underlying hypertension for more BP control.
The choices of drugs will be at discretion of treating physicians.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants Who Died Within 7 Days After Discharge From the Emergency Department
Time Frame: 7 days
|
Number of participants who died from hypertension-related events within 7 days after discharge from the emergency department.
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants Who Had Major Hypertensive-related Events After Discharge From the Emergency Department
Time Frame: 7 days
|
Participants who had major hypertensive-related events defined by those who had one or more of the followings: acute chest pain, heart failure, acute coronary syndromes, acute aortic syndromes, retinal/vitreous hemorrhage, hypertensive retinopathy, seizure, acute cerebrovascular diseases, hypertensive encephalopathy, which occurred within 7 days after discharge from emergency department.
|
7 days
|
|
Systolic Blood Pressure at Follow-up
Time Frame: 3 to 7 days
|
Systolic blood pressure at follow-up measured by physicians that were non-investigators and unaware of the study.
|
3 to 7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Khrongwong Musikatavorn, M.D., Faculty of Medicine, Chulalongkorn Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2015
Primary Completion (Actual)
December 1, 2015
Study Completion (Actual)
December 1, 2015
Study Registration Dates
First Submitted
August 25, 2015
First Submitted That Met QC Criteria
August 25, 2015
First Posted (Estimate)
August 27, 2015
Study Record Updates
Last Update Posted (Estimate)
April 11, 2016
Last Update Submitted That Met QC Criteria
March 13, 2016
Last Verified
February 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 397/57
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
Abant Izzet Baysal UniversityNot yet recruitingPRIMARY HYPERTENSIONTurkey (Türkiye)
-
SingHealth PolyclinicsNanyang PolytechnicEnrolling by invitationHypertension,EssentialSingapore
-
Hacettepe UniversityBozok UniversityCompletedHypertension | Arterial Hypertension | Systemic HypertensionTurkey (Türkiye)
-
BackBeat Medical IncNot yet recruitingHypertension, Systolic | Hypertension (HTN) | Heart Failure With Preserved Ejection Fraction (HFpEFGeorgia
-
Xuanwu Hospital, BeijingNot yet recruiting
-
Shenzhen Salubris Pharmaceuticals Co., Ltd.Not yet recruiting
-
Instituto de Cardiologia do Rio Grande do SulCompletedHypertension (HTN) | Hypertension ArterialBrazil
Clinical Trials on Antihypertensive meds
-
McGill UniversityMcGill University Health Centre/Research Institute of the McGill University...CompletedMedication Adherence | Mobile ApplicationCanada
-
University of MiamiBeta Tau Chapter of Sigma Theta Tau InternationalCompleted
-
Vanderbilt UniversityNational Institute on Aging (NIA)CompletedQuality of Life | Dementia | PolypharmacyUnited States
-
National Institute of Diabetes and Digestive and...CompletedHypertensive Renal DiseaseUnited States
-
Vanderbilt University Medical CenterNational Institute on Aging (NIA)CompletedPolypharmacy | Geriatric Syndromes | Care TransitionsUnited States
-
University of Alabama at BirminghamNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
NYU Langone HealthCompletedCoronary Artery Disease | Diabetes MellitusUnited States
-
Cedars-Sinai Medical CenterPatient-Centered Outcomes Research InstituteCompletedDepression | Heart FailureUnited States
-
Northwestern UniversityNot yet recruitingHypertension | Primary Health Care | Reproductive Behavior | Electronic Health Record
-
Medical University of South CarolinaNew York Presbyterian HospitalCompleted